Skip to content

Innoviva, Inc. INVA Deferred Revenue

Deferred Revenue at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$621K+515%
Alkermes logo
AlkermesALKS
$0-100%
Zymeworks logo
ZymeworksZYME
$2.08M-91.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$6.28M-23.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$69.2M-14.7%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s deferred revenue?
Innoviva, Inc. (INVA) reported deferred revenue of $3.68M in Q1 2026.
How has Innoviva, Inc.'s deferred revenue changed year-over-year?
Innoviva, Inc.'s deferred revenue increased by 267.0% year-over-year, from $1M to $3.68M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.